title: Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis.
abstract: An in vivo thromboplastin (TP)-induced venous stasis thrombosis model in rabbits was used to compare the efficacy of standard heparin with the selective factor Xa inhibitors, recombinant tick anticoagulant peptide (rTAP) and recombinant antistasin (rATS), in prophylactic prevention of thrombus formation. Heparin significantly reduced TP-induced clot formation at doses of 55 and 100 U kg-1h-1 yielding clot weights of 9 +/- 4 and 6 +/- 2%, respectively. Clot formation was significantly decreased by i.v. infusions of rTAP at doses of 21, 37 and 64 micrograms kg-1 min-1 resulting in normalized clot weights of 13 +/- 3, 8 +/- 2 and 2 +/- 1%, respectively. rATS was approximately 10-fold more potent than rTAP, reducing normalized clot weights to 16 +/- 5, 2 +/- 1 and 1 +/- 0.8% at rATS doses of 1.25, 2.5 and 5.0 micrograms kg-1 min-1, respectively. These data suggest that factor Xa-mediated inhibition of coagulation with rTAP and rATS is as effective as conventional anticoagulant treatment with heparin in preventing venous thrombosis.
authors.affiliation: Department of Pharmacology, Merck Sharp & Dohme Research Laboratories, West Point, PA 19486.
authors.forename: G P
authors.initials: GP
authors.lastname: Vlasuk
authors.forename: D
authors.initials: D
authors.lastname: Ramjit
authors.forename: T
authors.initials: T
authors.lastname: Fujita
authors.forename: C T
authors.initials: CT
authors.lastname: Dunwiddie
authors.forename: E M
authors.initials: EM
authors.lastname: Nutt
authors.forename: D E
authors.initials: DE
authors.lastname: Smith
authors.forename: R J
authors.initials: RJ
authors.lastname: Shebuski
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use*; D060829:Arthropod Proteins; D004195:Disease Models, Animal; D065427:Factor Xa Inhibitors; D006493:Heparin / Q000627:therapeutic use*; D036341:Intercellular Signaling Peptides and Proteins; D007447:Invertebrate Hormones / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D010455:Peptides / Q000097:blood / Q000627:therapeutic use*; D011817:Rabbits; D011994:Recombinant Proteins / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D060829:Arthropod Proteins; D065427:Factor Xa Inhibitors; D036341:Intercellular Signaling Peptides and Proteins; D007447:Invertebrate Hormones; D010455:Peptides; D011994:Recombinant Proteins; C063967:tick anticoagulant peptide; C053155:antistasin; D006493:Heparin